bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
The Pharma Data
APRIL 16, 2021
Lilly’s chief scientific officer and president of Lilly Research Laboratories. Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and the Institute of Microbiology, Chinese Academy of Science (IMCAS). “With the growing prevalence of variants in the U.S.
Let's personalize your content